Tonix Pharmaceuticals stock halted ahead of FDA approval news
SALT LAKE CITY - Franklin Covey Co. (NYSE:FC) announced Wednesday that its Board of Directors has approved replenishing the company’s authorization to repurchase up to $50 million of its outstanding common stock. The announcement comes as the company’s shares trade near their 52-week low of $18.32, having declined about 55% from their peak of $44.16. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.
The organizational performance improvement company also authorized the adoption of a 10b5-1 trading plan to facilitate consistent share repurchases in compliance with securities law.
As of May 31, 2025, Franklin Covey had repurchased approximately $17 million of its common stock on the open market in fiscal year 2025 and had approximately $28 million remaining under the Board’s prior $50 million repurchase authorization. The new reauthorization includes any amounts remaining under the existing program.
"We believe that making up to $50 million available in our share repurchase program and adopting a 10b5-1 plan are effective tools to return capital to shareholders," said Paul Walker, Chief Executive Officer, in a press release statement.
Share purchases under the program may be made from time to time in open market transactions, in privately negotiated deals, or otherwise, including pursuant to the 10b5-1 trading plan. The repurchase program has no time limit and may be modified, suspended, or discontinued at any time.
The timing and total amount of stock repurchases will depend upon business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations.
Franklin Covey provides organizational performance improvement services through directly owned and licensee partner offices in over 160 countries and territories.
In other recent news, Franklin Covey reported its financial results for the third quarter of 2025, which fell short of expectations. The company announced an earnings per share (EPS) of -$0.11, significantly missing the anticipated $0.32. Revenue also declined to $67.1 million, below the forecasted $77.39 million, representing a 9% decrease compared to the previous year. In a leadership update, Franklin Covey announced the promotion of Holly Procter to President of its Enterprise Division, effective September 1, 2025. Procter, who joined the company in June 2024, will succeed Jennifer C. Colosimo. Colosimo is departing after nearly 25 years with Franklin Covey. Procter has previously held leadership roles at companies such as LinkedIn and Gallup. These developments reflect recent changes and challenges at Franklin Covey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.